J&J drug produces responses in more than 1/3 of myeloma patients in ASCO data

The company will present data from the Phase I trial of teclistamab in an oral session at the ASCO virtual meeting later this month. The drug, a bispecific monoclonal antibody against the antigen BCMA, is a potential competitor to a similar therapy developed by Amgen.

Leave a Reply